相关实验视频
Updated: Jun 28, 2026

19:50
Interview: Protein Folding and Studies of Neurodegenerative Diseases
Published on: July 16, 2008
lysosomes 中的蛋白质加工:神经退行性疾病的新治疗点
R J Mayer1, M Landon, L Laszlo
1Department of Biochemistry, University of Nottingham Medical School, Queen's Medical Centre, UK.
Lancet (London, England)
|July 18, 1992
概括
神经元拥有众多的溶解体,这些溶解体可能参与神经退行性疾病,如质脑病和阿尔茨海默病. 准这些溶解体可能为治疗神经元损伤提供一种新的治疗策略.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 神经元含有大量的溶解体,这一特征尚未得到广泛认可.
- 溶解体与神经退行性疾病的发病有关,包括子疾病和阿尔茨海默病.
- 异常的蛋白 (PrPSc) 积累和β/A4粉样蛋白前体的形成发生在溶酶体相关器官细胞中.
研究的目的:
- 探索 lysosomes 在神经退行性疾病的分子病原性中的作用.
- 调查溶酶体系统操纵作为治疗方法的潜力.
主要方法:
- 在神经退行性疾病中的细胞生物学观察和分子遗传发现的审查.
- 对溶酶体相关器官中的蛋白质积累和形成途径的分析.
主要成果:
- 溶酶体相关器官被认为是产生异常蛋白 (PrPSc) 和β/A4蛋白的位置.
- 从溶解体释放出水解酶可能会导致主要神经元损伤.
结论:
- 细胞生物学见解对于理解神经退行途径至关重要.
- 针对溶酶体系统的治疗策略需要考虑治疗神经退行性疾病.
相关概念视频
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Lysosomes
Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
Delivery Pathways to the Lysosome
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

